Severe Sepsis and Septic Shock in the Emergency Department

Infectious Disease Clinics of North America

Volumn 22, Issue 1, 2008, Pages 1-31

  Talan, David A ^a,b,c   Moran, Gregory J ^a,b,c   Abrahamian, Fredrick M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Medical Center   (United States)

^c OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPICILLIN; BICARBONATE; CEFOTAXIME; CEFTRIAXONE; CLINDAMYCIN; CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; DROTRECOGIN; GENTAMICIN; HYDROCORTISONE; IMIPENEM; INSULIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; STEROID; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTIFICIAL VENTILATION; BLEEDING; CLINICAL RESEARCH; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFIDENCE INTERVAL; DRUG SUBSTITUTION; EMERGENCY WARD; HEMODYNAMICS; HERPES SIMPLEX ENCEPHALITIS; HUMAN; IN VITRO STUDY; INSULIN TREATMENT; LABORATORY DIAGNOSIS; LOW DRUG DOSE; MENINGITIS; PATIENT CARE; PELVIC INFLAMMATORY DISEASE; REVIEW; SEPSIS; SEPTIC SHOCK; SOFT TISSUE INFECTION; TIDAL VOLUME; UNITED STATES; URINARY TRACT INFECTION;

ADRENAL CORTEX HORMONES; ANTI-INFECTIVE AGENTS; EMERGENCY MEDICINE; EMERGENCY SERVICE, HOSPITAL; HEMODYNAMICS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROTEIN C; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; SHOCK, SEPTIC;

EID: 39649092106     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2007.09.005     Document Type: Review

References (143)

1. Dellinger R.P., Carlet J.M., Masur H., et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32 3 (2004) 858-872
2. McCaig L.F., and Burt C.W. National Hospital Ambulatory Medical Care Survey: 2001 emergency department summary. Adv Data 335 (2003) 1-29
3. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 7 (2001) 1303-1310
4. Wang H.E., Shapiro N.I., Angus D.C., et al. National estimates of severe sepsis in United States emergency departments. Crit Care Med 35 8 (2007) 1928-1936
5. Nguyen H.B., Rivers E.P., Abrahamian F.M., et al. Consensus guidelines for the treatment of severe sepsis and septic shock in the emergency department. Ann Emerg Med 48 1 (2006) 28-54
6. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 6 (1992) 864-874
7. Levy M.M., Fink M.P., Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29 4 (2003) 530-538
8. Talan D.A. Dear SIRS: it's time to return to sepsis as we have known it. [editorial]. Ann Emerg Med 48 5 (2006) 591-592
9. Shapiro N.I., Howell M.D., Bates D.W., et al. The association of sepsis syndrome and organ dysfunction with mortality in emergency department patients with suspected infection. Ann Emerg Med 48 5 (2006) 583-590
10. Dremsizov T., Clermont G., Kellum J.A., et al. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course?. Chest 129 4 (2006) 968-978
11. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 19 (2001) 1368-1377
12. Rangel-Frausto M.S., Pittet D., Costigan M., et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273 2 (1995) 117-123
13. Cornbleet P.J. Clinical utility of the band count. Clin Lab Med 22 1 (2002) 101-136
14. Novak R.W. The beleaguered band count. Clin Lab Med 13 4 (1993) 895-903
15. Wenz B., Gennis P., Canova C., et al. The clinical utility of the leukocyte differential in emergency medicine. Am J Clin Pathol 86 3 (1986) 298-303
16. Ardron M.J., Westengard J.C., and Dutcher T.F. Band neutrophil counts are unnecessary for the diagnosis of infection in patients with normal total leukocyte counts. Am J Clin Pathol 102 5 (1994) 646-649
17. Callaham M. Inaccuracy and expense of the leukocyte count in making urgent clinical decisions. Ann Emerg Med 15 7 (1986) 774-781
18. Kuppermann N., and Walton E.A. Immature neutrophils in the blood smears of young febrile children. Arch Pediatr Adolesc Med 153 3 (1999) 261-266
19. Shapiro N.I., Wolfe R.E., Moore R.B., et al. Mortality in Emergency Department Sepsis (MEDS) score: a prospectively derived and validated clinical prediction rule. Crit Care Med 31 3 (2003) 670-675
20. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336 4 (1997) 243-250
21. Vanderschueren S., De Weerdt A., Malbrain M., et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 28 6 (2000) 1871-1876
22. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 10 (2001) 699-709
23. Kinasewitz G.T., Yan S.B., Basson B., et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. [ISRCTN74215569]. Crit Care 8 2 (2004) R82-R90
24. Levraut J., Bounatirou T., Ichai C., et al. Reliability of anion gap as an indicator of blood lactate in critically ill patients. Intensive Care Med 23 4 (1997) 417-422
25. Iberti T.J., Leibowitz A.B., Papadakos P.J., et al. Low sensitivity of the anion gap as a screen to detect hyperlactatemia in critically ill patients. Crit Care Med 18 3 (1990) 275-277
26. Abramson D., Scalea T.M., Hitchcock R., et al. Lactate clearance and survival following injury. J Trauma 35 4 (1993) 584-588 [discussion 588-9]
27. Bakker J., Gris P., Coffernils M., et al. Serial blood lactate levels can predict the development of multiple organ failure following septic shock. Am J Surg 171 2 (1996) 221-226
28. Shapiro N.I., Howell M.D., Talmor D., et al. Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med 45 5 (2005) 524-528
29. Nguyen H.B., Rivers E.P., Knoblich B.P., et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 32 8 (2004) 1637-1642
30. Weil M.H., Michaels S., and Rackow E.C. Comparison of blood lactate concentrations in central venous, pulmonary artery, and arterial blood. Crit Care Med 15 5 (1987) 489-490
31. Murdoch I.A., Turner C., and Dalton R.N. Arterial or mixed venous lactate measurement in critically ill children. Is there a difference?. Acta Paediatr 83 4 (1994) 412-413
32. Gallagher E.J., Rodriguez K., and Touger M. Agreement between peripheral venous and arterial lactate levels. Ann Emerg Med 29 4 (1997) 479-483
33. Marshall J.C., Vincent J.L., Fink M.P., et al. Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 31 5 (2003) 1560-1567
34. Simon L., Gauvin F., Amre D.K., et al. Serum procalcitonin and c-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39 2 (2004) 206-217 (errata 2005;40:1386-8)
35. Tang B.M.P., Eslick G.D., and McLean A.S. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: a systematic review and meta-analysis. Lancet Infect Dis 7 3 (2007) 210-217
36. Jensen J.U., Heslet L., Jensen T.H., et al. Procalcitonin increase in early identification of critically ill patients at risk of mortality. Crit Care Med 34 10 (2006) 2596-2602
37. Weinstein M.P. Current blood culture methods and systems: clinical concepts, technology, and interpretation of results. Clin Infect Dis 23 1 (1996) 40-46
38. Cockerill III F.R., Wilson J.W., Vetter E.A., et al. Optimal testing parameters for blood cultures. Clin Infect Dis 38 12 (2004) 1724-1730
39. Mermel L.A., and Maki D.G. Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood. Ann Intern Med 119 4 (1993) 270-272
40. Lamy B., Roy P., Carret G., et al. What is the relevance of obtaining multiple blood samples for culture? A comprehensive model to optimize the strategy for diagnosing bacteremia. Clin Infect Dis 35 7 (2002) 842-850
41. Washington II J.A., and Ilstrup D.M. Blood cultures: issues and controversies. Rev Infect Dis 8 5 (1986) 792-802
42. Aronson M.D., and Bor D.H. Blood cultures. Ann Intern Med 106 2 (1987) 246-253
43. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2 (2007) S27-S72
44. Jones A.E., Focht A., Horton J.M., et al. Prospective external validation of the clinical effectiveness of an emergency department-based early goal directed therapy protocol for severe sepsis and septic shock. Chest 132 2 (2007) 425-432
45. Nguyen H.B., Corbett S.W., Steele R., et al. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality. Crit Care Med 35 4 (2007) 1105-1112
46. Shorr A.F., Micek S.T., Jackson W.L., et al. Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs?. Crit Care Med 35 5 (2007) 1257-1262
47. Otari R.M., Nguyen H.B., Huang D.T., et al. Early goal-directed therapy in severe sepsis ands septic shock revisited: concepts, controversies, and contemporary findings. Chest 130 4 (2006) 1579-1595
48. Marik P.E., and Varon J. Goal-directed therapy for severe sepsis. N Engl J Med 346 13 (2002) 1025-1026 author reply 1025-6
49. Jones A.E., and Kline J.A. Use of goal-directed therapy for severe sepsis and septic shock in academic emergency departments. Crit Care Med 33 8 (2005) 1888-1889
50. Shapiro N.I., Howell M.D., Talmor D., et al. Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol. Crit Care Med 34 4 (2006) 1025-1032
51. Micek S.T., Roubinian N., Heuring T., et al. Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med 34 11 (2006) 2707-2713
52. Randazzo M.R., Snoey E.R., and Levitt M.A. Binder K Accuracy of emergency physician assessment of left ventricular ejection fraction and central venous pressure using echocardiography. Acad Emerg Med 10 9 (2003) 973-977
53. DuPont H.L., and Spink W.W. Infections due to gram-negative organisms: an analysis of 860 patients with bacteremia at the University of Minnesota Medical Center. Medicine 48 4 (1969) 307-332
54. Freid M.A., and Vosti K.L. The importance of underlying disease in patients with gram-negative bacteremia. Arch Intern Med 121 5 (1968) 418-423
55. Bryant R.E., Hood A.F., Hood C.E., et al. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med 127 1 (1971) 120-128
56. Myerowitz R.L., Medeiros A.A., and O'Brien T.F. Recent experience with bacillemia due to gram-negative organisms. J Infect Dis 124 3 (1971) 239-246
57. Setia U., and Gross P.A. Bacteremia in a community hospital: spectrum and mortality. Arch Intern Med 137 12 (1977) 1698-1701
58. Weinstein M.P., Reller L.B., Murphy J.R., et al. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis 5 1 (1983) 35-53
59. Weinstein M.P., Murphy J.R., Reller L.B., et al. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis. Rev Infect Dis 5 1 (1983) 54-70
60. McCue J.D. Improved mortality in gram-negative bacillary bacteremia. Arch Intern Med 145 7 (1985) 1212-1216
61. Ispahani P., Pearson N.J., and Greenwood D. An analysis of community and hospital-acquired bacteraemia in a large teaching hospital in the United Kingdom. Q J Med 63 241 (1987) 427-440
62. Meyers B.R., Sherman E., Mendelson M.H., et al. Bloodstream infections in the elderly. Am J Med 86 4 (1989) 379-384
63. Leibovici L., Shraga I., Drucker M., et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 244 5 (1998) 379-386
64. Behrendt G., Schneider S., Brodt H.R., et al. Influence of antimicrobial treatment on mortality in septicemia. J Chemother 11 3 (1999) 179-186
65. Zaragoza R., Artero A., Camarena J.J., et al. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 9 5 (2003) 412-418
66. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 2 (1999) 462-474
67. Kang C.I., Kim S.H., Kim H.B., et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37 6 (2003) 745-751
68. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 1 (2000) 146-155
69. Yu V.L., Chiou C.C., Feldman C., et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 37 2 (2003) 230-237
70. Garnacho-Montaro J., Garcia-Garmendia J.L., Barrero-Almodovar A., et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31 12 (2003) 2742-2751
71. Valles J., Rello J., Ochagavia A., et al. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 123 5 (2003) 1615-1624
72. Cartwright K., Reilly S., White D., et al. Early treatment with parenteral penicillin in meningococcal disease. BMJ 305 6846 (1992) 143-147
73. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34 6 (2006) 1589-1596
74. Kumar A., Haery C., Paladugu B., et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 193 2 (2006) 251-258
75. Talan D.A., Guterman J.J., Overturf G.D., et al. Analysis of the emergency department management of bacterial meningitis. Ann Emerg Med 18 8 (1989) 856-862
76. Aronin S.I., Peduzzi P., and Quagliarello V.J. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 129 11 (1998) 862-869
77. Sands K.E., Bates D.W., Lanken P.N., et al. Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA 278 3 (1997) 234-240
78. Brun-Buisson C., Doyon F., Carlet J., et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 274 12 (1995) 968-974
79. Bochud P.Y., Glauser M.P., and Calandra T. Antibiotics in sepsis. Intensive Care Med 27 Suppl 1 (2001) S33-S48
80. Abraham E., Wunderink R., Silverman H., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273 12 (1995) 934-941
81. Brun-Buisson C., Doyon F., and Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med 154 3 Pt 1 (1996) 617-624
82. Cohen J., and Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24 9 (1996) 1431-1440
83. McCabe W.R., and Jackson G.G. Gram negative bacteremia. Arch Intern Med 110 (1962) 92-100
84. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 184 3 (1976) 333-341
85. Abraham E., Anzueto A., Gutierrez G., et al. Double-blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351 9107 (1998) 929-933
86. Saravolatz L.D., Wherry J.C., Spooner C., et al. Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-alpha. J Infect Dis 169 1 (1994) 214-217
87. Kieft H., Hoepelman A.I., Zhou W., et al. The sepsis syndrome in a Dutch university hospital. Clinical observations. Arch Intern Med 153 19 (1993) 2241-2247
88. Fisher Jr. C.J., Dhainaut J.F., Opal S.M., et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271 23 (1994) 1836-1843
89. Fisher Jr. C.J., Slotman G.J., Opal S.M., et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit Care Med 22 1 (1994) 12-21
90. Reinhart K., Wiegand-Lohnert C., Grimminger F., et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24 5 (1996) 733-742
91. Dhainaut J.F., Vincent J.L., Richard C., et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 23 9 (1995) 1461-1469
92. Opal S.M., Fisher Jr. C.J., Dhainaut J.F., et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25 7 (1997) 1115-1124
93. Bernard G.R., Wheeler A.P., Russell J.A., et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 336 13 (1997) 912-918
94. Mylotte J.M., Tayara A., and Goodnough S. Epidemiology of bloodstream infection in nursing home residents: evaluation in a large cohort from multiple homes. Clin Infect Dis 35 12 (2002) 1484-1490
95. Osih R.B., McGregor J.C., Rich S.E., et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 51 13 (2007) 839-844
96. Vanderkooi O.G., Low D.E., Green K., et al. Toronto Invasive Bacterial Disease Network. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 40 9 (2005) 1288-1297
97. Wenzel R.P., Sahm D.F., Thornsberry C., et al. In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy. Antimicrob Agents Chemother 47 10 (2003) 3089-3098
98. Karlowsky J.A., Jones M.E., Thornsberry C., et al. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis 40 Suppl 2 (2005) S89-S98
99. Karlowsky J.A., Thornsberry C., Critchley I.A., et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother 47 6 (2003) 1790-1797
100. Draghi D.C., Sheehan D.J., Hogan P., et al. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 49 12 (2005) 5024-5032
101. Chen D.K., McGeer A., de Azavedo J.C., et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 341 4 (1999) 233-239
102. Moran G.J., Krishnadasan A., Gorwitz R.J., et al., for The EMERGEncy ID NET Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355 7 (2006) 666-674
103. Centers for Disease Control. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 56 14 (2007) 325-329
104. Ruhe J.J., Smith N., Bradsher R.W., et al. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 44 6 (2007) 777-784
105. Szumowski J.D., Cohen D.E., Kanaya F., et al. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 51 2 (2007) 423-428
106. Dragi D.C., Sheehan D.F., Hogan P., et al. Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting. Diagn Microbiol Infect Dis 55 2 (2006) 129-133
107. Lewis II J.S., and Jorgensen J.H. Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned?. Clin Infect Dis 40 2 (2005) 280-285
108. Centers for Disease Control. Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients-United States, 2005. MMWR Morb Mortal Wkly Rep 56 9 (2007) 197-199
109. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 44 12 (2007) 1543-1548
110. Mohr J.F., and Murray B.E. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 44 12 (2007) 1536-1542
111. Lodise Jr. T.P., McKinnon P.S., Levine D.P., et al. Impact of empirical therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin susceptible Staphylococcus aureus. Antimicrob Agents Chemother 51 10 (2007) 3731-3733
112. Stevens D.L., Ma Y., Salmi D.B., et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 195 2 (2007) 202-211
113. Harbarth S., Nobre V., and Pittet D. Does antibiotic selection impact patient outcome?. Clin Infect Dis 44 1 (2007) 87-93
114. Hunter T.H. Use of streptomycin in treatment of bacterial endocarditis. Am J Med 2 (1947) 436-442
115. Fowler Jr. V.G., Boucher H.W., Corey G.R., et al. Paptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 7 (2006) 653-655
116. Howden B.P., Ward P.B., Charles P.G.P., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38 4 (2004) 521-528
117. Weigelt J., Itani K., Stevens D., et al., the Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49 6 (2005) 2260-2266
118. Wunderink R.G., Rello J., Cammarata S.K., et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 5 (2003) 1789-1797
119. Jensen A.G., Wachmann C.H., Espersen F., et al. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med 162 1 (2002) 25-32
120. Bohnen J.M., Marshall J.C., Fry D.E., et al. Clinical and scientific importance of source control in abdominal infections: summary of a symposium. Can J Surg 42 2 (1999) 122-126
121. Knaus W.A., Draper E.A., Wagner D.P., et al. APACHE II: a severity of disease classification system. Crit Care Med 13 10 (1985) 818-829
122. FDA briefing document. Drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris, BLA#125029/0. Food and Drug Administration. Available at: www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1.htm. Accessed September 12, 2001.
123. Abraham E.A., LaTerre P.F., Garg R., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353 123 (2005) 1332-1341
124. Nadel S., Goldstein B., Williams M.D., et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomized controlled trial. Lancet 369 9564 (2007) 836-843
125. Ely E.W., Bernard G.R., and Vincent J.L. Activated protein C for severe sepsis. N Engl J Med 347 13 (2002) 1035-1036
126. Vincent J.L., Bernard G.R., Beale R., et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33 10 (2005) 2266-2277
127. Vincent J.-L., O'Brien Jr. J.O., Wheeler A., et al. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. Crit Care 10 3 (2006) R74
128. Warren H.S., Suffredini A.F., Eichacker P.Q., et al. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 347 13 (2002) 1027-1030
129. Laterre P.-F., Garber G., Levy H., et al. Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study. Crit Care Med 33 5 (2005) 952-961
130. Haley M., Cui X., Minneci P.C., et al. Recombinant human activated protein C in sepsis: Previous concerns and current usage. Therapy 1 (2004) 123-129
131. Lilly Plans New Clinical Trial Of Xigris(R). Available at: http://www.medicalnewstoday.com/articles/63959.php. Accessed August 20, 2007.
132. Annane D., Sebille V., Troche G., et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 283 8 (2000) 1038-1045
133. Lamberts S.W., Bruining H.A., and de Jong F.H. Corticosteroid therapy in severe illness. N Engl J Med 337 18 (1997) 1285-1292
134. Sprung C.L., Caralis P.V., Marcial E.H., et al. The effects of high-dose corticosteroids in patients with septic shock: a prospective, controlled study. N Engl J Med 311 18 (1984) 1137-1143
135. Bone R.C., Fisher Jr. C.J., Clemmer T.P., et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317 11 (1987) 653-658
136. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317 11 (1987) 659-665
137. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 7 (2002) 862-871
138. Sprung C.L., Annane D., Briegel J., et al. Hydrocortisone therapy for patients with septic shock. N Eng J Med 358 2 (2008) 111-124
139. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 342 18 (2000) 1301-1308
140. Van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 345 19 (2001) 1359-1367
141. Van den Berghe G., Wilmer A., Hermans G., et al. Intensive insulin therapy in the medical ICU. N Engl J Med 354 5 (2006) 449-461
142. Cooper D.J., Walley K.R., Wiggs B.R., et al. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med 112 3 (1990) 492-498
143. Mathieu D., Neviere R., Billard V., et al. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit Care Med 19 11 (1991) 1352-1356